Long-term chemotherapy-related cardiovascular morbidity

Research output: Contribution to journalReview articlepeer-review

97 Citations (Scopus)

Abstract

As a consequence of-the successful use of chemotherapy in the treatment of curable neoplasms such as germ cell tumours and malignant lymphomas, and the increasing application of primary and adjuvant chemotherapy for various tumour types. the number of patients with a prolonged life expectancy after treatment is rising. Attention to long-term side-effects. including cardiovascular toxicity, is therefore of growing importance. In this review we evaluate the literature on long-term cardiovascular toxicity related to chemotherapy in adult patients. Two categories of patient with favourable life expectancy have been reviewed, namely patients cured of metastatic disease by chemotherapy and patients treated with adjuvant chemotherapy. In the first, category. the literature on long-term cardiovascular morbidity in survivors of metastatic testicular cancer and lymphomas is discussed. while in the second category this is done for patients treated with adjuvant chemotherapy for breast and colon cancer As well as the direct toxic effects of chemotherapy on the cardiovascular system. the indirect toxic effects such as chemotherapy-related metabolic changes that may cause cardiovascular morbidity are also discussed. (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish
Pages (from-to)429-447
Number of pages19
JournalCANCER TREATMENT REVIEWS
Volume26
Issue number6
DOIs
Publication statusPublished - Dec-2000

Keywords

  • chemotherapy
  • cardiotoxicity
  • vascular toxicity
  • long-term
  • side-effect
  • GERM-CELL TUMORS
  • CISPLATIN-BASED CHEMOTHERAPY
  • LEFT-VENTRICULAR DYSFUNCTION
  • TESTICULAR CANCER-PATIENTS
  • HIGH-DOSE CYCLOPHOSPHAMIDE
  • OPERABLE BREAST-CANCER
  • VENO-OCCLUSIVE DISEASE
  • NON-HODGKINS-LYMPHOMA
  • ANTHRACYCLINE-INDUCED CARDIOTOXICITY
  • CONTAINING COMBINATION CHEMOTHERAPY

Fingerprint

Dive into the research topics of 'Long-term chemotherapy-related cardiovascular morbidity'. Together they form a unique fingerprint.

Cite this